Ms. Sally Kuah has been appointed as Country Manager for Wellesta Healthcare Sdn Bhd, Malaysia. This legal entity will focus on Pharmaceutical Business of Wellesta in Malaysia. Sally will join us from 1st July 2021.

Her last position was the Business Unit Director for MSD Malaysia, Singapore and Brunei. She has extensive experience with 20 years in pharmaceutical industry in multiple therapeutic areas such as Vaccine, Neurology, Psychiatry, Diabetes, Ophthalmology and Cardiovascular.

Ms. Sally Kuah started her career as Product Specialist for Sanofi Pasteur and moved to marketing role after 2 years. During her stint in Sanofi Pasteur, she managed both the paediatric and adults/traveller’s vaccines. After Sanofi, she moved to Novartis as the Product Manager and continued to take on bigger roles over the years as Sales and Marketing Manager and Franchise Head. In Novartis, she handled multiple portfolios from neurosciences, ophthalmology, heart failure cardiovascular and diabetes. She also played an integral role to merge the Alcon and Novartis ophthalmology portfolios and successfully led the entire team as a combined unit.

Ms. Sally Kuah moved to MSD as the Business Unit Director for the Primary Care Business, with expanded responsibilities covering 3 countries. She has experience as a member of the Country Leadership Team for more than 8 years. She has led multiple country-initiated projects which touched on people and transforming work cultures, process simplifications, pilots and innovations.

She is a science degree graduate in Biotechnology (first class honors) from Universiti Putra Malaysia and holds an MBA from Charles Sturt University, Australia.

We at Wellesta see good opportunities in Malaysian Pharmaceutical & Nutraceutical Markets. We see a strong growth opportunity in both segments. We are sure that Ms. Sally Kuah’s experience and leadership will help our Malaysia business plan for Pharma business to achieve our vision and mission in Malaysia.Our Nutraceutical, Direct to Consumer Business in Malaysia will be under Wellesta Truelife Sdn. Bhd. entity which is led by Mr. Joe Pramesh Ganesaguru.

Both Ms. Sally Kuah & Mr. Joe P will report to Milan Paleja, Chairman and MD of the Wellesta Group.

We welcome Ms. Sally to Wellesta family and wish her all success & joy in her new position.

Mr Brendan Khor has been appointed as Regulatory Affairs Manager for Wellesta Healthcare Sdn Bhd, Malaysia..

Prior to joining Wellesta, Mr. Brendan was with DCH Auriga as a Regulatory Affairs Manager. He is a registered pharmacist in Malaysia with over 10 years of working experience in the pharmaceutical industry. He started his career started as a Hospital Pharmacist in Queen Elizabeth Hospital, Sabah Malaysia and later worked with Sunward Pharmaceutical and DCH Auriga as a Regulatory Affairs Manager.

He possesses in-depth knowledge of the local regulatory environment for pharmaceutical products and medical devices. His strength lies in his ability of working collaboratively with cross-functional teams by providing

consultative strategic advices in early development, gap analysis and management of product registration application submission throughout the product lifecycle. His areas of expertise include regulatory affairs, pharmacovigilance, quality assurance compliance and project management. He has led multiple projects related to business development and regulatory affairs during his tenure in previous companies.

Mr Brendan was awarded a study scholarship by International Medical University and completed his Master Degree of Pharmacy in University of Strathclyde, Glasgow Scotland.

We at Wellesta see good growth opportunities in the Malaysian Pharmaceutical & Nutraceutical Markets. We welcome him to our Wellesta family and wish him all success & joy in his new position. He will report to Ms Sally Kuah, Country Head for Wellesta Healthcare Malaysia.

Mr George Lye is the Key Account Manager for Wellesta Healthcare Sdn Bhd, Malaysia.

Prior to joining Wellesta, Mr George was the Commercial Planning Manager for Aspen Medical Malaysia. He has more than 10 years of commercial experience in the pharmaceutical industry in multiple therapeutic areas such as Oncology, Haematology, Women’s Health, Biosimilar and Generic Portfolio.

Mr George started his career as Product Specialist for Rhone-Poulenc and progressed to a Product Management role. He held the sales and brand management role in Orient EuroPharma for prescription medicine portfolio supporting Malaysia, Singapore and Brunei. During his stint with Pfizer, he managed the key portfolios such as Oncology, Haematology and Women’s health. Throughout his career, he has achieved successful brand launches and innovative marketing campaigns for multiple pharma brands.

Mr George is a science degree graduate in Biochemistry from Campbell University, USA and holds an MBA from the University of Wales Trinity Saint David, UK.

We at Wellesta see good growth opportunities in the Malaysian Pharmaceutical & Nutraceutical Markets. We welcome Mr George to our Wellesta family and look forward to his dedicated contribution in the overall management and growth of Wellesta business in Malaysia. He will report to Ms Sally Kuah, Country Head for Wellesta Healthcare Malaysia.

Wellesta Holdings Pte Ltd and Altamira Therapeutics Ltd have broaden their agreement for marketing and distribution of Bentrio™ by including two attractive new markets. In addition to India, Indonesia, Malaysia, Singapore, Taiwan and Vietnam, Wellesta will also start promoting and selling Bentrio™ in Philippines & Morocco, upon registration in these two countries.

Bentrio™ is a drug-free nasal spray intended for personal protection against airborne viruses and allergens. Upon application in the nose, Bentrio™ forms a protective gel layer on the nasal mucosa. It is designed to reduce the risk of upper respiratory tract viral infections and promote alleviation of allergic symptoms.  

Wellesta has successfully registered Bentrio in Malaysia, whilst In Singapore, Bentrio has been classified as a Class A medical device, since the signing of marketing & distribution agreement in October 2021, and is currently in process of obtaining marketing clearance in other six countries covered by the agreement. 

Mr. Milan Paleja, Chairman & MD of Wellesta is excited about extending benefits of Bentrio™ to additional geographies and said “Happy to expand collaboration with Altamira Therapeutics to market and distribute Bentrio™ in Philippines and Morocco as well, which shows great potential for business and further help protect larger masses against airborne viruses and allergens.” 

  About Wellesta Holdings  
Wellesta Holdings Pte Ltd is a fast-growing healthcare company headquartered in Singapore with a direct market presence in Southeast Asia, India & North Africa. The company aims to serve clients and consumers through commercial and marketing support using an innovative approach across the Wellesta value chain.   

Founded in 2019 by two executives with more than 70 years of cumulated experience in leading multinational companies (MNCs) in health care, the company has since grown to more than 540 employees.

Wellesta works with companies to expand their presence in SEA, India & North Africa, as a strategic partner for companies present in these markets and act as a representative for companies that are not present in these markets and would like to sell/market their products in the region.

The company operates in a spectrum of business verticals under Partner Brands and Own Brands including Pharmaceutical, Nutraceuticals, OTC and Medical devices, which is being led by industry-proven leaders at HQ & country level. Wellesta works as an extended arm for principals through win-win partnership and provide superior quality products and services at the right price, by working at full compliance and transparency in our business approach.

About Altamira Therapeutics  
Altamira Therapeutics is dedicated to developing therapeutics that address important unmet medical needs. The Company is currently active in three areas: the development of RNA therapeutics for extrahepatic therapeutic targets (OligoPhore™ / SemaPhore™ platforms; preclinical), nasal sprays for protection against airborne viruses and allergens (Bentrio™; commercial) or the treatment of vertigo (AM-125; Phase 2), and the development of therapeutics for intratympanic treatment of tinnitus or hearing loss (Keyzilen® and Sonsuvi®, Phase 3). The Company was founded in 2003 and is headquartered in Hamilton, Bermuda with its main operations in Basel, Switzerland. The shares of Altamira Therapeutics Ltd. trade on the NASDAQ Capital Market under the symbol “CYTO.”   

Mr. Lawrence Lye has been appointed as Business Finance Planning & Analyst Manager for Malaysia with effect from 7th March 2022.

Mr. Lawrence is a FCCA member with over 9 years of working experience within both the MNC and Public Practice environment. In his previous role, he was the Controllership business analyst with AstraZeneca Asia Pacific Business Services for 4 years supporting India and Taiwan markets. His responsibilities included overseeing month end close process, ensuring timely & accurate delivery of financial information to stakeholders and taking accountability for effective operation of relevant financial reporting controls.

Prior to joining AstraZeneca, he was with BDO as an audit manager, his portfolios ranges from trading, manufacturing, plantation, services, and information technology industry. He was also involved in initial public offering engagements and the company has successfully listed on the main market of Bursa Malaysia.

Mr. Lawrence has a BSc (Hons) Degree in Applied Accounting from Oxford Brookes University (OBU) and he is a Fellow Member of Association of Chartered Certified Accountants (FCCA).

We at Wellesta see good growth opportunities in the Malaysian Pharmaceutical. We welcome Mr. Lawrence to our Wellesta family and look forward to his dedicated contribution in the overall management and growth of Wellesta business in Malaysia.

He will report to Ms Sally Kuah, Country Head for Wellesta Healthcare Malaysia.

Mr. Lee Gau Hsiang has been appointed as Sales Manager for Malaysia with effect from 1st July 2022. He joined Wellesta from DCH Auriga, where he was the National Sales Manager.

Gau Hsiang started his career as a Product Specialist in Servier Malaysia, and then moved to Novartis Corp (M) Sdn Bhd, where he progressed to take on sales management roles. In the last 20+ years in the pharmaceutical industry, Gau Hsiang has accumulated an extensive commercial experience in multiple therapeutic areas, encompassing both general and speciality medicine, such as Cardiovascular, Diabetes, Ophthalmology, Infectious diseases and Generic Portfolio. He has also worked across various health sectors and managed new launched and established products. Beyond sales management, he was also instrumental in various market access projects like MoH blue book listing, private sector MEAs and special access via Import permit.

Some of his notable achievements include leading the team to being awarded MoH tender for 6 consecutive years and securing alternative fundings (Dasar Baru route, Pensioner Funds) through innovative approaches.

Mr. Lee is a Biomedical Sciences degree graduate from Universiti Kebangsaan Malaysia.

He will report to Ms Sally Kuah, Country Head for Wellesta Healthcare Malaysia.

We welcome Mr. Lee Gau Hsiang to our Wellesta family and wish him great success in his new position.

Ms. Madge Jiang has been appointed as Finance Business Manager for Singapore with effect from 17 January 2022.

Madge brings with her over 12 years of finance and business operation experience from the hospitality and F&B industry, working across organizations such as Aman resort international and PUTIEN Group. As a CPA, she specializing in financing planning & analysis, budgeting, forecasting and internal control, providing insights into business health to support strategic and growth planning operation. Madge earned a Master of professional accounting from the Macquarie University and Business Administration from the Southern Cross university in Australia.

At Wellesta, we see opportunity for good growth within the Singapore Pharmaceutical & OTC industry with addition of Madge to the Wellesta team. We welcome her to our Wellesta family and look forward to her dedicated contribution in the overall management and growth of Wellesta business in Singapore.

Madge will report to Mr. Paul Lim, Country Head for Singapore, and OTC Lead for Singapore, Philippines and Indonesia.

Mr Jason Low has been appointed as Associate Product Manager (Pharmaceutical) for Singapore with effect from 11 October 2021.

Jason brings with him over 6 years of clinical and pharmaceutical experience from the healthcare and pharmaceutical industry, working across organizations such as MSD, Abbott and National Healthcare Group. As a licensed Pharmacist with business acumen, he has played a pivotal role in the launch of multiple brands under the vaccine and anti-infective portfolio, achieving significant quarter on quarter growth during his tenure with MSD.

Jason earned a Master of Business Administration from the University of Manchester and a Bachelor of Science (Pharmacy) from the National University of Singapore.

Jason will report to Mr. Paul Lim, Country Head for Singapore, and OTC Lead for Singapore, Philippines and Indonesia.

At Wellesta, we see opportunity for good growth within the Singapore Pharmaceutical & OTC industry with the addition of Jason to the Wellesta team. We welcome him to our Wellesta family and look forward to his dedicated contribution in the overall management and growth of Wellesta business in Singapore.

Mr. Dennis Lim has been appointed as Regulatory Specialist for Singapore with effect from 6 Sep 2021.

Prior to joining Wellesta Singapore, Dennis worked as a senior pharmacist in Changi General Hospital where he provided professional clinical pharmacy services to various departments. In particular, he started with specialties including Cardiology, Dermatology, Otorhinolaryngology, Gastroenterology, Ophthalmology, General Medicine, and Renal Medicine, before focusing on Geriatric Medicine, Neurology and Psychiatry. With several years of experience in a fast-paced restructured hospital, he is adept at implementing innovative practices and procedures to improve process efficiency, staff productivity and patient care experiences.

He is a registered Pharmacist with a Bachelor of Pharmacy degree from the National University of Singapore where he graduated with 1st Class Honors.

At Wellesta, we see opportunities for good growth within the Singapore Pharmaceutical & OTC industry with the addition of Dennis to the Wellesta team. We welcome him to our Wellesta family and look forward to his dedicated contribution in the overall management and growth of Wellesta business in Singapore.

Prior to joining Wellesta, Ms. Angela worked with A. Menarini as a Senior Product Manager. Her marketing experience spans over 8 years of handling both local and regional portfolios in Singapore and across the Southeast Asia region in the pharmaceutical industry in multiple therapeutic areas such as Gynaecology, Obstetrics, Dermatology, Aesthetics, ENT, Urology, Men’s Health & Gastroenterology.

Ms. Angela Tham started her career as a Product Executive for Hyphens Pharma in 2009 and rose to ranks in 2013 as an Assistant Manager role handling market development for 2 years where she started to get involved in the Indonesia Market. With her personal and working experience in both sales and marketing, she started mentoring and supporting both the Singapore team as a Product Manager and the Indonesia sales team in opening new opportunities.

In 2016, she was promoted to Associate Regional Product Manager which expanded her coverage across Hyphens regional offices in Singapore, Malaysia, Indonesia, Philippines and Vietnam focusing on the Dermatology business unit. She is well experienced in handling new product launches, organizing regional symposiums and working on new product developments. She has also been involved in clinical studies conducted across the region, working with various societies and hospital departments.

With her drive to pursue an all-rounded career, Ms. Angela Tham decided to move to A. Menarini Singapore in 2019 as a Senior Product Manager. In her 2 years with Menarini, she was mainly involved in launching 3 new brands including the product development of an anti-aging cosmetic range, working on formulation, branding and packaging design.

Ms. Angela Tham is a science degree graduate majoring in Biomedical Science and Microbiology from the University of Queensland, Australia.

We are very sure that Angela’s experience locally & SEA will help our business growth agenda. Ms. Angela will report to Milan Paleja, Chairman and MD of the Wellesta Group.

We welcome Ms. Angela to the Wellesta family and wish her great success in her new position.

Naari Pte Ltd & Wellesta Holdings Pte Ltd are pleased to announce its joint venture for Singapore as NaariEsta Pte Ltd. Naari will be investing 65% and Wellesta would invest 35% in the joint venture. This will be a vertically integrated, women’s health focused company: NaariEsta Pte Ltd, operating in Singapore and Brunei markets.

Naari Pte is headquartered in Singapore and has development and manufacturing capabilities for fermentation intermediates, active pharmaceutical ingredients and finished dosage forms. Apart from a vast portfolio of generic APIs and FDFs, Naari has other innovative products at various stages of development and clinical trials. Naari’s mission is to have a comprehensive product portfolio that serves the needs of women throughout their lives – from puberty, through pregnancies, menopause and post-menopause.

Wellesta is a company headquartered in Singapore and its main specialty is in Marketing, Brand Management, Sales & Operations with world-class standards in its business approach and compliance. Its focus is on the Asia Pacific market to provide pharmaceutical and medical devices and consumer healthcare products. Wellesta aims to be a valued partner to healthcare companies in serving the community in Singapore and the Asia Pacific with a cost-effective and wide range of pharmaceutical and healthcare products, with women-care being one of the focus areas. The joint-venture offers win-win synergies for both companies.

The joint venture between the two companies provides opportunities for synergy, with Naari bringing in products from both the prescription and the OTC line, as well as medical devices and other products. Wellesta’s comprehensive understanding of the market aims to provide the right platform for the products to expand towards to greater heights. The joint venture will be a union of the two companies offering a comprehensive women's health portfolio with an aim to provide products and be a partner in the journey of overall wellness of women in Singapore. With niche and diversified product portfolio, NaariEsta would have access to women's healthcare market in Singapore of about USD 20 million and will start realizing the revenues from April'2021 onwards.

Both Wellesta and Naari operate based on the principles of High Integrity, Value-added partner and Full Transparency for our principals. With this, NaariEsta’s mission to serve women’s needs by providing high-quality healthcare products and services at an optimum price will be achieved through this joint venture which will be driven by our commitment, in-market expertise and efficient enactment.

We are pleased to announce the collaboration of Wellesta and Cureleads.

Wellesta is a company headquartered in Singapore and support Healthcare companies to expand their reach of products for larger access to patients & brand building by way of offering sales, marketing & distribution. It also helps smaller MNC’s & Biotech companies as launch pad for their products to be launched in Asia Pacific. Wellesta is led by Industry Proven leaders at HQ & Country level.

Cureleads is a company headquartered in Dubai & Beirut and aspires to transform patient’s lives by leading the path to cure specialty and rare diseases. It is founded by highly profiled industry leaders regionally and globally.

Cureleads is involved in the business of distribution and marketing of medicinal and pharmaceutical products in Middle East, Dubai & North Africa.

Wellesta is in the business of marketing, brand creation, sales & distribution of medicinal and Healthcare products with focus on Asia Pacific.

With this collaboration both companies can help companies to get coverage across Asia Middle East & Africa (AMEA) geographies. Both companies operate on the principles of High Integrity, Value added partner & Full transparency for our Principals. This alliance will help companies get a partner which provides excellent reach in AMEA countries.

Apart from this, both companies will also provide bilateral support for each other through medical talks, health fairs, newsletters and websites or such other media. They will carry out joint research on the demographics, risk profiles and care needs of the population in both territories from time to time.

Thus, Wellesta’s goal to support and provide high quality healthcare products & services at optimum price to improve health access to masses, and Curelead’s goal to lead the transformation of patients’ lives & curing speciality diseases will be accomplished through this collaboration in Asia Middle East & Africa. Our focus would be driven through our dedicated efforts, strong in-market experience, best-in class capabilities, determination and excellent execution.

Mr. Norman Phua has been appointed as OTC Product Manager for Singapore with effect from 10 May, 2021.

Norman brings with him over 10 years of brand and marketing experience from the FMCG and Consumer Goods industry, working across organizations such as Nestle, Fonterra, F&N and Tefal. He has managed and grown various brands under his care though new product launches, brand building activations and profitability management.

Norman holds a Bachelor of Business Management degree from the Royal Melbourne Institute of Technology.

At Wellesta, we see opportunity for good growth within the Singapore Pharmaceutical & OTC industry with addition of Norman to the Wellesta team. We welcome him to our Wellesta family and look forward to his dedicated contribution in the overall management and growth of Wellesta business in Singapore.

Norman will report to Mr. Paul Lim, Country Head for Singapore, and OTC Lead for Singapore, Philippines and Indonesia.

Dr. Tan Wei Liang has been appointed as Associate Product Manager for Singapore with effect from 1st October, 2020.

Prior to joining Wellesta, Dr. Tan worked at AstraZeneca where he helped launched Immuno- oncology into the Singapore Market. Dr. Tan started his pharmaceutical career in medical affairs at Bayer where he was involved in various medical excellence and governance projects for the Asia Pacific region and was part of the team reviewing Patient Support Programs across the markets.

Dr. Tan is highly passionate about innovation and possesses both commercial and medical affairs experience in the pharmaceutical industry. He completed his Ph.D. in Biological Sciences with the Nanyang Technological University in Singapore.

We at Wellesta see opportunity for good growth within Singapore Pharmaceutical & OTC industry with addition of Dr. Tan to Wellesta team. We welcome Dr. Tan Wei Liang to our Wellesta family and look forward to his dedicated contribution in the overall management and growth of Wellesta business in Singapore.

Dr. Tan will report to Paul Lim, Country Head for Singapore and OTC Lead for Singapore, Malaysia and Indonesia.

Mr. Vincent Chua has been appointed as Key Account Manager, OTC for Singapore business with effect from 1st August, 2020.

Mr. Chua comes with deep industry knowledge and in-market experience. His previous portfolio includes various sales management roles with Zuellig Pharma and Pfizer where he had built and lead a team of merchandisers and promoters to launch VMS products and achieved strong double-digit sales growth in the VMS categories.

Mr. Chua is highly motivated and comes with over 12 years of experience in the pharmaceutical and consumer healthcare over-the-counter (OTC) industry where he had built and maintained a healthy relationship with customers in both Modern and General Trade. He had exposure to regional coverage that extended to Malaysia and Brunei.

Mr. Chua holds a Bachelor of science degree - Business Management from the University of Bradford. Mr. Vincent will report to Mr. Paul Lim, Country Head for Singapore, and OTC Lead for Singapore, Malaysia and Indonesia.

We at Wellesta see opportunity for good growth within Singapore Pharmaceutical & OTC industry with addition of Mr. Vincent Chua to Wellesta team. We welcome Mr. Vincent Chua to our Wellesta family and look forward to his dedicated contribution in the overall management and growth of Wellesta business in Singapore.

Mr. Paul Lim has been appointed as Country Head for Singapore and OTC Lead for Singapore, Malaysia and Indonesia with effect from 1st March, 2020.

Mr. Lim previously worked at Church & Dwight where he launched and achieved market leadership in numerous countries in the Nasal care and VMS categories as OTC Lead - Asia Pacific. Mr. Lim is a highly motivated and experienced commercial leader with over 18 years of experience in the pharmaceutical and consumer health industry across Asia Pacific.

With his expertise and robust experience, he has held various key commercial roles in multinational companies such as Pfizer, Alcon and Church & Dwight. He also enabled Alcon Singapore to extend its leadership in the pharmaceutical franchise of ophthalmology as Business Unit Head.

He holds Bachelor of Business degree from the University of Central Queensland and has completed his coursework for Global MBA from University of London.

We at Wellesta see good opportunity for Singapore Pharma & OTC Market and in other SE emerging markets. With addition of Mr. Lim to Wellesta team, would help driving opportunities and meet the Vision and Mission of our company.

Mr. Lim will report to Milan Paleja, Director of Wellesta Healthcare Singapore Pte Ltd & also Chairman & MD of Wellesta Group.

We welcome Mr. Paul Lim, who is now based in Singapore, to our Wellesta family. We look forward for his dedicated contribution in the overall management and growth of Wellesta business in Singapore as well as being the Lead for the OTC Businesses in Malaysia and Indonesia.

KC Liau has been appointed as a Marketing Lead for Wellesta Healthcare Sdn. Bhd., Malaysia.

Prior to joining Wellesta, Mr. KC Liau was with GSK Pharmacuetical as a Business Unit Head for General Medicines. He is a seasoned Sales and Marketing leader with more than 20 years of increasing responsibility and experience across various healthcare sectors including innovative and generic medicines (MSD, Novartis, Sandoz, GSK), medical devices and disposables (Tyco Healthcare), as well as consumer healthcare (Bayer Consumer).

He has extensive experience and knowledge in many key therapy areas that includes Respiratory, Allergy, Urology, Neurology, Gastrointestinal, HIV, Anti-Infectives, CV, HepC, Pain, Osteoporosis; growing the various channels of the business (Government, Private Hospital, Clinics, Pharmacy and the Brunei market) considerably in his prior roles.

On top of that, he is an accomplished people leader, and has worked to grow and develop his teams’ talents both personally and professionally in all the organizations that he has worked in.

He is a government sponsored graduate from the University of Malaya with a degree in Biomedical Science (Hons) and an employer sponsored MBA in General Management from University of Hull (UK).

He will report to Ms Sally Kuah, Country Head for Wellesta Healthcare Malaysia.

We at Wellesta see good growth opportunities in the Malaysian Pharmaceutical markets. We welcome him to our Wellesta family and wish him all success in his new position.